GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets

Area of Science:

• Neuroscience
• Neurodegenerative Diseases
• Pharmacology

Background:

• Parkinson's disease (PD) involves dopamine neuron loss, with L-DOPA as primary treatment.
• L-DOPA offers symptomatic relief but does not halt disease progression and can cause dyskinesia.
• Glial cell line-derived neurotrophic factor (GDNF) shows potential in preclinical models for neuroprotection in PD.

Purpose of the Study:

• To investigate the therapeutic effects of GDNF on L-DOPA-induced dyskinesia in a primate model of Parkinson's disease.
• To assess GDNF's impact on motor function, behavioral symptoms, and underlying neurobiology.

Main Methods:

• MPTP-treated common marmosets exhibiting L-DOPA-induced dyskinesia received intraventricular GDNF or saline injections.
• Motor disability, locomotor activity, and dyskinesia severity were evaluated.
• Post-mortem analysis included tyrosine hydroxylase-positive neuron counts in the substantia nigra and neurotransmitter mRNA expression in the striatum.

Main Results:

• GDNF administration significantly improved motor disability and locomotor activity.
• GDNF treatment reduced the severity of L-DOPA-induced dyskinesia and motor deficits.
• GDNF increased tyrosine hydroxylase-positive neurons in the substantia nigra but did not alter striatal dopamine terminal binding.

Conclusions:

• Intraventricular GDNF administration is a viable strategy for improving motor function in Parkinson's disease models.
• GDNF effectively diminishes L-DOPA-induced dyskinesia, potentially by restoring nigral dopaminergic transmission or modulating striatal pathways.
• GDNF shows promise as a therapeutic agent for Parkinson's disease, addressing both motor symptoms and treatment-related side effects.